Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Apply
Trastuzumab & Pertuzumab
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step